Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients with Schizophrenia

Tsuyoshi Okada; Hikaru Hori; Naomi Hasegawa; Atsunobu Murata; Yoshitaka Kyou; Fumitoshi Kodaka; Hitoshi Iida; Shinichiro Ochi; Yoshikazu Takaesu; Takashi Tsuboi; Jun Ichi Iga; Kayo Ichihashi; Hiroyuki Muraoka; Ryuji Furihata; Norio Yasui-Furukori; Masahide Usami; Toshiaki Onitsuka; Kazuyoshi Ogasawara; Hiromi Tagata; Masahiro Takeshima; Kazutaka Ohi; Shusuke Numata; Naoki Hashimoto; Hiroki Yamada; Manabu Makinodan; Hiroshi Komatsu; Akitoyo Hishimoto; Hirotaka Yamagata; Mikio Kido; Chika Kubota; Kiyokazu Atake; Hisashi Yamada; Tatsuya Nagasawa; Junya Matsumoto; Kenichiro Miura; Ken Inada; Koichiro Watanabe; Shiro Suda; Ryota Hashimoto

doi:10.1097/JCP.0000000000001604

Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients with Schizophrenia

Tsuyoshi Okada, Hikaru Hori, Naomi Hasegawa, Atsunobu Murata, Yoshitaka Kyou, Fumitoshi Kodaka, Hitoshi Iida, Shinichiro Ochi, Yoshikazu Takaesu, Takashi Tsuboi, Jun Ichi Iga, Kayo Ichihashi, Hiroyuki Muraoka, Ryuji Furihata, Norio Yasui-Furukori, Masahide Usami, Toshiaki Onitsuka, Kazuyoshi Ogasawara, Hiromi Tagata, Masahiro TakeshimaKazutaka Ohi, Shusuke Numata, Naoki Hashimoto, Hiroki Yamada, Manabu Makinodan, Hiroshi Komatsu, Akitoyo Hishimoto, Hirotaka Yamagata, Mikio Kido, Chika Kubota, Kiyokazu Atake, Hisashi Yamada, Tatsuya Nagasawa, Junya Matsumoto, Kenichiro Miura, Ken Inada, Koichiro Watanabe, Shiro Suda, Ryota Hashimoto

Neurological and Psychiatric Disorders

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	591-593
Number of pages	3
Journal	Journal of Clinical Psychopharmacology
Volume	42
Issue number	6
DOIs	https://doi.org/10.1097/JCP.0000000000001604
Publication status	Published - 2022 Nov 1

ASJC Scopus subject areas

Psychiatry and Mental health
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/JCP.0000000000001604

Cite this

Okada, T., Hori, H., Hasegawa, N., Murata, A., Kyou, Y., Kodaka, F., Iida, H., Ochi, S., Takaesu, Y., Tsuboi, T., Iga, J. I., Ichihashi, K., Muraoka, H., Furihata, R., Yasui-Furukori, N., Usami, M., Onitsuka, T., Ogasawara, K., Tagata, H., ... Hashimoto, R. (2022). Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients with Schizophrenia. Journal of Clinical Psychopharmacology, 42(6), 591-593. https://doi.org/10.1097/JCP.0000000000001604

Okada, T, Hori, H, Hasegawa, N, Murata, A, Kyou, Y, Kodaka, F, Iida, H, Ochi, S, Takaesu, Y, Tsuboi, T, Iga, JI, Ichihashi, K, Muraoka, H, Furihata, R, Yasui-Furukori, N, Usami, M, Onitsuka, T, Ogasawara, K, Tagata, H, Takeshima, M, Ohi, K, Numata, S, Hashimoto, N, Yamada, H, Makinodan, M, Komatsu, H, Hishimoto, A, Yamagata, H, Kido, M, Kubota, C, Atake, K, Yamada, H, Nagasawa, T, Matsumoto, J, Miura, K, Inada, K, Watanabe, K, Suda, S & Hashimoto, R 2022, 'Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients with Schizophrenia', Journal of Clinical Psychopharmacology, vol. 42, no. 6, pp. 591-593. https://doi.org/10.1097/JCP.0000000000001604

@article{96d76ebbb83445ecbc2d5e2ad1ee87d3,

title = "Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients with Schizophrenia",

author = "Tsuyoshi Okada and Hikaru Hori and Naomi Hasegawa and Atsunobu Murata and Yoshitaka Kyou and Fumitoshi Kodaka and Hitoshi Iida and Shinichiro Ochi and Yoshikazu Takaesu and Takashi Tsuboi and Iga, {Jun Ichi} and Kayo Ichihashi and Hiroyuki Muraoka and Ryuji Furihata and Norio Yasui-Furukori and Masahide Usami and Toshiaki Onitsuka and Kazuyoshi Ogasawara and Hiromi Tagata and Masahiro Takeshima and Kazutaka Ohi and Shusuke Numata and Naoki Hashimoto and Hiroki Yamada and Manabu Makinodan and Hiroshi Komatsu and Akitoyo Hishimoto and Hirotaka Yamagata and Mikio Kido and Chika Kubota and Kiyokazu Atake and Hisashi Yamada and Tatsuya Nagasawa and Junya Matsumoto and Kenichiro Miura and Ken Inada and Koichiro Watanabe and Shiro Suda and Ryota Hashimoto",

note = "Funding Information: This study was supported by the Japan Agency for Medical Research and Development, grant numbers JP 18dk0307060 and JP 19dk0307083; Health and Labor Science Research Grants (H29-Seishin-Ippan-001, 19GC1201); the Japanese Society of Neuropsychopharmacology; and the Japanese Society of Mood Disorders. The funders had no role in the study design, data collection and analyses, decision to publish, or preparation of the manuscript. ",

year = "2022",

month = nov,

day = "1",

doi = "10.1097/JCP.0000000000001604",

language = "English",

volume = "42",

pages = "591--593",

journal = "Journal of Clinical Psychopharmacology",

issn = "0271-0749",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients with Schizophrenia

AU - Okada, Tsuyoshi

AU - Hori, Hikaru

AU - Hasegawa, Naomi

AU - Murata, Atsunobu

AU - Kyou, Yoshitaka

AU - Kodaka, Fumitoshi

AU - Iida, Hitoshi

AU - Ochi, Shinichiro

AU - Takaesu, Yoshikazu

AU - Tsuboi, Takashi

AU - Iga, Jun Ichi

AU - Ichihashi, Kayo

AU - Muraoka, Hiroyuki

AU - Furihata, Ryuji

AU - Yasui-Furukori, Norio

AU - Usami, Masahide

AU - Onitsuka, Toshiaki

AU - Ogasawara, Kazuyoshi

AU - Tagata, Hiromi

AU - Takeshima, Masahiro

AU - Ohi, Kazutaka

AU - Numata, Shusuke

AU - Hashimoto, Naoki

AU - Yamada, Hiroki

AU - Makinodan, Manabu

AU - Komatsu, Hiroshi

AU - Hishimoto, Akitoyo

AU - Yamagata, Hirotaka

AU - Kido, Mikio

AU - Kubota, Chika

AU - Atake, Kiyokazu

AU - Yamada, Hisashi

AU - Nagasawa, Tatsuya

AU - Matsumoto, Junya

AU - Miura, Kenichiro

AU - Inada, Ken

AU - Watanabe, Koichiro

AU - Suda, Shiro

AU - Hashimoto, Ryota

N1 - Funding Information: This study was supported by the Japan Agency for Medical Research and Development, grant numbers JP 18dk0307060 and JP 19dk0307083; Health and Labor Science Research Grants (H29-Seishin-Ippan-001, 19GC1201); the Japanese Society of Neuropsychopharmacology; and the Japanese Society of Mood Disorders. The funders had no role in the study design, data collection and analyses, decision to publish, or preparation of the manuscript.

PY - 2022/11/1

Y1 - 2022/11/1

UR - http://www.scopus.com/inward/record.url?scp=85141892249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141892249&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000001604

DO - 10.1097/JCP.0000000000001604

M3 - Letter

C2 - 36193896

AN - SCOPUS:85141892249

SN - 0271-0749

VL - 42

SP - 591

EP - 593

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

IS - 6

ER -

Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients with Schizophrenia

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this